Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback